Iodothyronine deiodinases and cancer

Journal of Endocrinological Investigation

Volumn 34, Issue 9, 2011, Pages 716-728

  Piekielko Witkowska A ^a   Nauman, A ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Cancer; Hypothyroidism; Iodothyronine deiodinases; Selenoproteins; Thyroid hormone

Indexed keywords

IODOTHYRONINE; IODOTHYRONINE DEIODINASE; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG;

BASAL CELL CARCINOMA; BRAIN TUMOR; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE LOCUS; HUMAN; HYPOPHYSIS TUMOR; HYPOTHYROIDISM; KIDNEY CANCER; LIVER TUMOR; LUNG CANCER; MESOTHELIOMA; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; REVIEW; THYROID TUMOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; DISEASE PROGRESSION; HUMANS; HYPOTHYROIDISM; IODIDE PEROXIDASE; ISOENZYMES; NEOPLASMS; RECEPTORS, THYROID HORMONE; THYROID HORMONES;

EID: 84856201054     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7754     Document Type: Review

References (170)

1. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010, 31: 139-70.
2. Marsili A, Zavacki AM, Harney JW, Larsen PR. Physiological role and regulation of iodothyronine deiodinases: a 2011 update. J Endocrin Invest 2011, 34: 395-407.
3. Gereben B, Zavacki AM, Ribich S, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 2008, 29: 898-938.
4. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 2005, 115: 2524-33. (Pubitemid 41266215)
5. Laurberg P, Vestergaard H, Nielsen S, et al. Sources of circulating 3,5,3′-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 2007, 92: 2149-56. (Pubitemid 46997114)
6. St Germain DL, Galton VA, Hernandez A. Minireview: Defining the roles of the iodothyronine deiodinases: current concepts and challenges. Endocrinology 2009, 150: 1097-107.
7. Williams GR. Actions of thyroid hormones in bone. Endokrynol Pol 2009, 60: 380-8.
8. Bassett JH, Boyde A, Howell PG, et al. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. Proc Natl Acad Sci U S A 2010, 107: 7604-9.
9. Horn S, Heuer H. Thyroid hormone action during brain development: more questions than answers. MoI Cell Endocrinol 2010, 315: 19-26.
10. Puzianowska-Kuznicka M, Pietrzak M, Turowska O, Nauman A. Thyroid hormones and their receptors in the regulation of cell proliferation. Acta Biochim Pol 2006, 53: 641-50. (Pubitemid 46090114)
11. Dentice M, Ambrosio R, Salvatore D. Role of type 3 deiodinase in cancer. Expert Opin Ther Targets 2009, 13: 1363-73.
12. Ohba K, Yoshioka T, Muraki T. Identification of two novel splicing variants of human type II iodothyronine deiodinase mRNA. Mol Cell Endocrinol 2001, 172: 169-75. (Pubitemid 32098408)
13. Gereben B, Kollár A, Harney JW, Larsen PR. The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression. Mol Endocrinol 2002, 16: 1667-79. (Pubitemid 34743681)
14. Piekielko-Witkowska A, Master A, Wojcicka A, et al. Disturbed expression of type 1 iodothyronine deiodinase splice variants in human renal cancer. Thyroid 2009, 19: 1105-13.
15. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002, 23: 38-89. (Pubitemid 34185306)
16. Zhuo P, Diamond AM. Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim Biophys Acta 2009, 1790: 1546-54.
17. Moustafa ME, Carlson BA, El-Saadani MA, et al. Selective inhibition of selenocysteine tRNA maturation and selenoprotein synthesis in transgenic mice expressing isopentenyladenosine-deficient selenocysteine tRNA. Mol Cell Biol 2001, 21: 3840-52. (Pubitemid 32466995)
18. Amaral AF, Cantor KP, Silverman DT, Malats N. Selenium and bladder cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010, 19: 2407-15.
19. Steevens J, van den Brandt PA, Goldbohm RA, Schouten U. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology 2010, 138: 1704-13.
20. Steinbrecher A, Méplan C, Hesketh J, et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev 2010, 19: 2958-68.
21. García-Solís P, Alfaro Y, Anguiano B, et al. Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancer promotion. Mol Cell Endocrinol 2005, 236: 49-57. (Pubitemid 40726337)
22. Shrivastava A, Tiwari M, Sinha RA, et al. Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway. J Biol Chem 2006, 281: 19762-71. (Pubitemid 44035478)
23. Galton VA, Schneider MJ, Clark AS, St Germain DL. Life without thyroxine to 3,5,3′-triiodothyronine conversion: studies in mice devoid of the 5′-deiodinases. Endocrinology 2009, 150: 2957-63.
24. Hercbergs AH, Ashur-Fabian O, Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes 2010, 17: 432-6.
25. Piekielko-Witkowska A. Thyroid hormone receptors and cancer. Hot Thyroidology 2010, 1/10.
26. Aranda A, Martínez-lglesias O, Ruiz-Llorente L, García-Carpizo V, Zambrano A. Thyroid receptor: roles in cancer. Trends Endocrinol Metab 2009, 20: 318-24.
27. Martinez MB, Ruan M, Fitzpatrick LA. Altered response to thyroid hormones by breast and ovarian cancer cells. Anticancer Res 2000, 20: 4141-6. (Pubitemid 32141755)
28. Martinez MB, Ruan M, Fitzpatrick LA. Altered response to thyroid hormones by prostate and breast cancer cells. Cancer Chemother Pharmacol 2000, 45: 93-102. (Pubitemid 30090239)
29. Hall LC, Salazar EP, Kane SR, Liu N. Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol 2008, 109: 57-66.
30. Cestari SH, Figueiredo NB, Conde SJ, et al. Influence of estradiol and triiodothyronine on breast cancer cell lines proliferation and expression of estrogen and thyroid hormone receptors. Arq Bras Endocrinol Metabol 2009, 53: 859-64.
31. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 2002, 21: 761-8. (Pubitemid 34146288)
32. González-Sancho JM, Figueroa A, López-Barahona M, López E, Beug H, Muñoz A. Inhibition of proliferation and expression of T1 and cyclin D1 genes by thyroid hormone in mammary epithelial cells. Mol Carcinog 2002, 34: 25-34. (Pubitemid 34461654)
33. Hsieh ML, Juang HH. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J Androl 2005, 26: 422-8.
34. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate 2008, 68: 610-9.
35. Poplawski P, Nauman A. Thyroid hormone - triiodothyronine - has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1) - role of E2F4, E2F5 and p107, p130. Thyroid Res 2008, 1: 5.
36. Murakami M, Araki O, Morimura T, et al. Expression of type II iodothyronine deiodinase in brain tumors. J Clin Endocrinol Metab 2000, 85: 4403-6. (Pubitemid 32055405)
37. de Souza Meyer EL, Dora JM, Wagner MS, Maia AL. Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma. Clin Endocrinol (Oxf) 2005, 62: 672-8. (Pubitemid 40825936)
38. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001, 98: 15044-9. (Pubitemid 34013966)
39. Ambroziak M, Pachucki J, Stachlewska-Nasfeter E, Nauman J, Nauman A. Disturbed expression of type 1 and type 2 iodothyronine deiodinase as well as titf1/nkx2-1 and pax-8 transcription factor genes in papillary thyroid cancer. Thyroid 2005, 15: 1137-46. (Pubitemid 41720720)
40. Arnaldi LA, Borra RC, Maciel RM, Cerutti JM. Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 2005, 15: 210-21. (Pubitemid 40418688)
41. Murakami M, Araki O, Hosoi Y, et al. Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 2001, 142: 2961-7. (Pubitemid 32575533)
42. Brtko J, Bobálová J, Podoba J, Schmutzler C, Köhrle J. Thyroid hormone receptors and type I iodothyronine 5′-deiodinase activity of human thyroid toxic adenomas and benign cold nodules. Exp Clin Endocrinol Diabetes 2002, 110: 166-70. (Pubitemid 34619627)
43. Wawrzynska L, Sakowicz A, Rudzinski P, Langfort R, Kurzyna M. The conversion of thyroxine to triiodothyronine in the lung: comparison of activity of type I iodothyronine 5′ deiodinase in lung cancer with peripheral lung tissues. Monaldi Arch Chest Dis 2003, 59: 140-5. (Pubitemid 37420132)
44. Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000, 343: 185-9. (Pubitemid 30489216)
45. Bessho K, Etani Y, Ichimori H, et al. Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism. Eur J Pediatr 2010, 169: 215-21.
46. Huang SA, Fish SA, Dorfman DM, et al. A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab 2002, 87: 4457-61. (Pubitemid 35247024)
47. Sabatino L, lervasi G, Ferrazzi P, Francesconi D, Chopra IJ. A study of iodothyronine 5′-monodeiodinase activities in normal and pathological tissues in man and their comparison with activities in rat tissues. Life Sci 2000, 68: 191-202.
48. Pachucki J, Ambroziak M, Tanski Z, Luczak J, Nauman J, Nauman A. Type I 5′-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J Endocrinol Invest 2001, 24: 253-61. (Pubitemid 32435505)
49. Master A, Wójcicka A, Piekiełko-Witkowska A, et al. Untranslated regions of thyroid hormone receptor beta 1 mRNA are impaired in human clear cell renal cell carcinoma. Biochim Biophys Acta 2010, 1802: 995-1005.
50. Dentice M, Luongo C, Huang S, et al. Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc Natl Acad Sci U S A 2007, 104: 14466-71. (Pubitemid 350003284)
51. LeBron BA, Pekary AE, Mirell C, Hahn TJ, Hershman JM. Thyroid hormone 5′-deiodinase activity, nuclear binding, and effects on mitogenesis in UMR-106 osteoblastic osteosarcoma cells. J Bone Miner Res 1989, 4: 173-8. (Pubitemid 19121790)
52. Morimura T, Tsunekawa K, Kasahara T, et al. Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 2005, 146: 2077-84. (Pubitemid 40396919)
53. Calvo RM, Roda JM, Obregón MJ, Morreale de Escobar G. Thyroid hormones in human tumoral and normal nervous tissues. Brain Res 1998, 801: 150-7. (Pubitemid 28401658)
54. Nauman P, Bonicki W, Michalik R, Warzecha A, Czernicki Z. The concentration of thyroid hormones and activities of iodothyronine deiodinases are altered in human brain gliomas. Folia Neuropathol 2004, 42: 67-73. (Pubitemid 38979241)
55. Tannahill LA, Visser TJ, McCabe CJ, et al. Dysregulation of iodothyronine deiodinase enzyme expression and function in human pituitary tumours. Clin Endocrinol (Oxf) 2002, 56: 735-43. (Pubitemid 34785904)
56. Kim BW, Daniels GH, Harrison BJ, et al. Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J Clin Endocrinol Metab 2003, 88: 594-8. (Pubitemid 36207796)
57. Meyer EL, Goemann IM, Dora JM, Wagner MS, Maia AL. Type 2 iodothyronine deiodinase is highly expressed in medullary thyroid carcinoma. Mol Cell Endocrinol 2008, 289: 16-22.
58. Debski MG, Pachucki J, Ambroziak M, Olszewski W, Bar-Andziak E. Human breast cancer tissue expresses high level of type 1 5′-deiodinase. Thyroid 2007, 17: 3-10. (Pubitemid 46214716)
59. Rihn BH, Mohr S, McDowell SA, et al. Differential gene expression in mesothelioma. FEBS Lett 2000, 480: 95-100.
60. Curcio C, Baqui MM, Salvatore D, et al. The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Chem 2001, 276: 30183-7.
61. Pinna G, Meinhold H, Hiedra L, et al. Elevated 3,5-diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors. J Clin Endocrinol Metab 1997, 82: 1535-42. (Pubitemid 27200431)
62. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008, 8: 743-54.
63. Dentice M, Bandyopadhyay A, Gereben B, et al. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol 2005, 7: 698-705. (Pubitemid 40975751)
64. Lupulescu A. Hormonal regulation of epidermal tumor development. J Invest Dermatol 1981, 77: 186-95. (Pubitemid 12231616)
65. Huang SA. Deiodination and cellular proliferation: parallels between development, differentiation, tumorigenesis, and now regeneration. Endocrinology 2009, 150: 3-4.
66. Ruppe MD, Huang SA, Jan de Beur SM. Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase. Thyroid 2005, 15: 1369-72.
67. Hassan MM, Kaseb A, Li D, et al. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 2009, 49: 1563-70.
68. Hellevik AI, Asvold BO, Bjøro T, Romundstad PR, Nilsen TI, Vatten U. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 2009, 18: 570-4.
69. Cristofanilli M, Yamamura Y, Kau SW, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005, 103: 1122-8. (Pubitemid 40328081)
70. Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J. Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res 2010, 12: R33.
71. Bhargav PR, Mishra A, Agarwal G, Agarwal A, Verma AK, Mishra SK. Prevalence of hypothyroidism in benign breast disorders and effect of thyroxine replacement on the clinical outcome. World J Surg 2009, 33: 2087-93.
72. Burke RE, McGuire WL. Nuclear thyroid hormone receptors in a human breast cancer cell line. Cancer Res 1978, 38: 3769-73. (Pubitemid 9045204)
73. Bracke ME, Van Larebeke NA, Vyncke BM, Mareel MM. Retinoic acid modulates both invasion and plasma membrane ruffling of MCF-7 human mammary carcinoma cells in vitro. Br J Cancer 1991, 63: 867-72.
74. Martínez-Iglesias O, García-Silva S, Regadera J, Aranda A. Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One 2009, 4: e6428.
75. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010, 15: 117-34.
76. Martínez-Iglesias O, Garcia-Silva S, Tenbaum SP, et al. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res 2009, 69: 501-9.
77. Leonard JL. Non-genomic actions of thyroid hormone in brain development. Steroids 2008, 73: 1008-12.
78. Dentice M, Marsili A, Ambrosio R, et al. The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. J Clin Invest 2010, 120: 4021-30.
79. Piehl S, Hoefig CS, Scanlan TS, Köhrle J. Thyronamines - Past, Present, and Future. Endocr Rev 2011, 32: 64-80.
80. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, et al. Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet Cytogenet 2004, 148: 123-8. (Pubitemid 38083339)
81. Micci F, Haugom L, Ahlquist T, et al. Genomic aberrations in borderline ovarian tumors. J Transl Med 2010, 8: 21.
82. Bièche I, Khodja A, Lidereau R. Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. Genes Chromosomes Cancer 1999, 24: 255-63. (Pubitemid 29070165)
83. el-Rifai W, Tarmo L, Hemmer S, et al. DNA copy number losses at 1p32-pter in monozygotic twins concordant for breast cancer. Cancer Genet Cytogenet 1999, 112: 169-72. (Pubitemid 29322743)
84. Opocher G, Schiavi F, Vettori A, et al. Fine analysis of the short arm of chromosome 1 in sporadic and familial pheochromocytoma. Clin Endocrinol (Oxf) 2003, 59: 707-15. (Pubitemid 37491574)
85. Menon AG, Rutter JL, von Sattel JP, et al. Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene 1997, 14: 611-6. (Pubitemid 27090964)
86. Kim NR, Cho SJ, Suh YL. Allelic loss on chromosomes 1p32, 9p21, 13q14, 16q22, 17p, and 22q12 in meningiomas associated with meningioangiomatosis and pure meningioangiomatosis. J Neurooncol 2009, 94: 425-30.
87. Simon M, von Deimling A, Larson JJ, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 1995, 55: 4696-701.
88. Bello MJ, de Campos JM, Vaquera J, Kusak ME, Sarasa JL, Rey JA. High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet 2000, 120: 30-6. (Pubitemid 30410774)
89. Chang IB, Cho BM, Moon SM, Park SH, Oh SM, Cho SJ. Loss of heterozygosity at 1p, 7q, 17p, and 22q in meningiomas. J Korean Neurosurg Soc 2010, 48: 14-9.
90. Rajaram V, Brat DJ, Perry A. Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers. Hum Pathol 2004, 35: 1413-8. (Pubitemid 39601583)
91. Mori K, Yoshida K, Kayama T, et al. Thyroxine 5-deiodinase in human brain tumors. J Clin Endocrinol Metab 1993, 77: 1198-202. (Pubitemid 23345469)
92. Dichamp C, Taillibert S, Aguirre-Cruz L, et al. Loss of 14q chromosome in oligodendroglial and astrocytic tumors. J Neurooncol 2004, 67: 281-5. (Pubitemid 39137358)
93. Sánchez-Franco F, Fernández L, Fernández G, Cacicedo L. Thyroid hormone action on ACTH secretion. Horm Metab Res 1989, 21: 550-2. (Pubitemid 19255449)
94. Giustina A, Wehrenberg WB. Influence of thyroid hormones on the regulation of growth hormone secretion. European Journal of Endocrinology 1995, 133: 646-53. (Pubitemid 26022221)
95. Barrera-Hernandez G, Soo Park K, Dace A, Zhan Q, Cheng S. Thyroid hormone-induced cell proliferation in GC cells is mediated by changes in G1 cyclin/cyclin-dependent kinase levels and activity. Endocrinology 1999, 140: 5267-74.
96. Quintanar-Stephano A, Valverde C. Mitogenic effects of thyroxine and TRH on thyrotrophs and somatotrophs of the anterior pituitary gland in thyroidectomized rats. J Endocrinol 1997, 154: 149-53. (Pubitemid 27304358)
97. Stahl JH, Kendall SK, Brinkmeier ML, et al. Thyroid hormone is essential for pituitary somatotropes and lactotropes. Endocrinology 1999, 140: 1884-92. (Pubitemid 29149262)
98. Itagaki Y, Yoshida K, Ikeda H, et al. Thyroxine 5′-deiodinase in human anterior pituitary tumors. J Clin Endocrinol Metab 1990, 71: 340-4.
99. Baur A, Buchfelder M, Köhrle J. Expression of 5′-deiodinase enzymes in normal pituitaries and in various human pituitary adenomas. Eur J Endocrinol 2002, 147: 263-8.
100. Carr J, Bown NP, Case MC, Hall AG, Lunec J, Tweddle DA. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genet Cytogenet 2007, 172: 127-38. (Pubitemid 46043573)
101. Hoshi M, Shiwaku HO, Hayashi Y, Kaneko Y, Horii A. Deletion mapping of 14q32 in human neuroblastoma defines an 1,100-kb region of common allelic loss. Med Pediatr Oncol 2000, 35: 522-5.
102. Zhou Y, Ye H, Martin-Subero JI, et al. The pattern of genomic gains in salivary gland MALT lymphomas. Haematologica 2007, 92: 921-7. (Pubitemid 350147792)
103. Rao PH, Roberts D, Zhao YJ, et al. Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res 2008, 14: 5181-7.
104. Kim TM, Yim SH, Lee JS, et al. Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 2005, 11: 8235-42.
105. Chizhikov V, Zborovskaya I, Laktionov K, et al. Two consistently deleted regions within chromosome 1p32-pter in human non-small cell lung cancer. Mol Carcinog 2001, 30: 151-8. (Pubitemid 32274078)
106. Wiech T, Nikolopoulos E, Weis R, et al. Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. Lab Invest 2009, 89: 385-97.
107. Ghadimi BM, Grade M, Mönkemeyer C, et al. Distinct chromosomal profiles in metastasizing and nonmetastasizing colorectal carcinomas. Cell Oncol 2006, 28: 273-81. (Pubitemid 44950098)
108. Bando T, Kato Y, Ihara Y, Yamagishi F, Tsukada K, Isobe M. Loss of heterozygosity of 14q32 in colorectal carcinoma. Cancer Genet Cytogenet 1999, 111: 161-5. (Pubitemid 29232868)
109. Al-Mulla F, AlFadhli S, Al-Hakim AH, Going JJ, Bitar MS. Metastatic recurrence of early-stage colorectal cancer is linked to loss of heterozygosity on chromosomes 4 and 14q. J Clin Pathol 2006, 59: 624-30. (Pubitemid 43886047)
110. Kim TM, Yim SH, Shin SH, et al. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer 2008, 123: 2808-15.
111. Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol 2004, 41: 292-8. (Pubitemid 39177634)
112. Qin LX, Tang ZY, Ye SL, et al. Chromosome 8p deletion is associated with metastasis of human hepatocellular carcinoma when high and low metastatic models are compared. J Cancer Res Clin Oncol 2001, 127: 482-8.
113. Chen M, Ye Y, Yang H, et al. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 2009, 125: 2342-8.
114. Toma MI, Grosser M, Herr A, et al. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 2008, 10: 634-42. (Pubitemid 351883879)
115. Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol 1997, 183: 151-5. (Pubitemid 27436017)
116. Herbers J, Schullerus D, Müller H, et al. Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas. Genes Chromosomes Cancer 1997, 19: 29-35. (Pubitemid 27193717)
117. Wang ZC, Lin M, Wei LJ, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004, 64: 64-71. (Pubitemid 38114083)
118. Jung SH, Shin SH, Yim SH, Choi HS, Lee SH, Chung YJ. Integrated analysis of copy number alteration and RNA expression profiles of cancer using a high-resolution whole-genome oligonucleotide array. Exp Mol Med 2009, 41: 462-70.
119. Aarts M, Dannenberg H, deLeeuw RJ, et al. Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1-0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes Chromosomes Cancer 2006, 45: 83-93. (Pubitemid 46930864)
120. Roque L, Nunes VM, Ribeiro C, Martins C, Soares J. Karyotypic characterization of papillary thyroid carcinomas. Cancer 2001, 92: 2529-38. (Pubitemid 33049435)
121. Hallor KH, Staaf J, Bovée JV, et al. Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res 2009, 15: 2685-94.
122. Lindholm PM, Salmenkivi K, Vauhkonen H, et al. Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 2007, 119: 46-52.
123. Flordal Thelander E, Ichimura K, Collins VP, et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 2007, 31: 1219-30.
124. Espinet B, Salaverria I, Beà S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer 2010, 49: 439-51.
125. Agueli C, Cammarata G, Salemi D, et al. 14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a. Am J Hematol 2010, 85: 575-8.
126. Gittoes NJ, McCabe CJ, Verhaeg J, Sheppard MC, Franklyn JA. Thyroid hormone and estrogen receptor expression in normal pituitary and nonfunctioning tumors of the anterior pituitary. J Clin Endocrinol Metab 1997, 82: 1960-7. (Pubitemid 127495218)
127. Fujarewicz K, Jarzab M, Eszlinger M, et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer 2007, 14: 809-26. (Pubitemid 350074069)
128. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J. Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 2002, 87: 1120-8. (Pubitemid 36121076)
129. Schreck R, Schnieders F, Schmutzler C, Köhrle J. Retinoids stimulate type I iodothyronine 5′- deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994, 79: 791-8.
130. Hoftijzer HC, Liu YY, Morreau H, et al. Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. Eur J Endocrinol 2009, 160: 631-8.
131. Pasca di Magliano M, Di Lauro R, Zannini M. Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci U S A 2000, 97: 13144-9.
132. Friedrichsen S, Christ S, Heuer H, et al. Regulation of iodothyronine deiodinases in the Pax8-/- mouse model of congenital hypothyroidism. Endocrinology 2003, 144: 777-84. (Pubitemid 36262844)
133. Miyauchi A, Takamura Y, Ito Y, et al. 3,5,3′-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. J Clin Endocrinol Metab 2008, 93: 2239-42. (Pubitemid 351831541)
134. García-Solís P, Aceves C. 5′Deiodinase in two breast cancer cell lines: effect of triiodothyronine, isoproterenol and retinoids. Mol Cell Endocrinol 2003, 201: 25-31. (Pubitemid 36434278)
135. Toyoda N, Zavacki AM, Maia AL, Harney JW, Larsen PR. A novel retinoid X receptor-independent thyroid hormone response element is present in the human type 1 deiodinase gene. Mol Cell Biol 1995, 15: 5100-12.
136. Beech SG, Walker SW, Arthur JR, Lee D, Beckett GJ. Differential control of type-I iodothyronine deiodinase expression by the activation of the cyclic AMP and phosphoinositol signalling pathways in cultured human thyrocytes. J Mol Endocrinol 1995, 14: 171-7.
137. Miller WR. Regulatory subunits of PKA and breast cancer. Ann N Y Acad Sci 2002, 968: 37-48. (Pubitemid 34721870)
138. Kwakkel J, Wiersinga WM, Boelen A. Differential involvement of nuclear factor-kappaB and activator protein-1 pathways in the interleukin-1beta-mediated decrease of deiodinase type 1 and thyroid hormone receptor beta1 mRNA. J Endocrinol 2006, 189: 37-44. (Pubitemid 43670699)
139. Jin L, Yuan RQ, Fuchs A, et al. Expression of interleukin-1beta inhuman breast carcinoma. Cancer 1997, 80: 421-34. (Pubitemid 27323412)
140. Pinto AE, Leite V, Soares J. Clinical implications of molecular markers in follicular cell-derived thyroid cancer. J Expert Rev Mol Diagn 2009, 9: 679-94.
141. Cengiz SE, Cetinkaya E, Altin S, et al. Nutritional and prognostic significance of sick euthyroid syndrome in non-small cell lung cancer patients. Intern Med 2008, 47: 211-6. (Pubitemid 351377281)
142. Tanski Z. Low T3 Syndrome in patients suffering from renal cell clear carcinoma (RCC). The dependance on its diameter (T) and grading (G). Urologia Polska (Polish Journal of Urology) 2000, 53: 3.
143. Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol 2010, 205: 1-13.
144. Debaveye Y, Ellger B, Mebis L, Darras VM, Van den Berghe G. Regulation of tissue iodothyronine deiodinase activity in a model of prolonged critical illness. Thyroid 2008, 18: 551-60. (Pubitemid 351667830)
145. Mebis L, Langouche L, Visser TJ, Van den Berghe G. The type II iodothyronine deiodinase is upregulated in skeletal muscle during prolonged critical illness. J Clin Endocrinol Metab 2007, 92: 3330-3. (Pubitemid 47236410)
146. Gresner P, Gromadzinska J, Jablonska E, Kaczmarski J, Wasowicz W. Expression of selenoproteincoding genes SEPP1, SEP15 and hGPX1 in non-small cell lung cancer. Lung Cancer 2009, 65: 34-40.
147. Ratnasinghe D, Tangrea JA, Andersen MR, et al. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 2000, 60: 6381-3.
148. Jablonska E, Gromadzinska J, Sobala W, Reszka E, Wasowicz W. Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism. Eur J Nutr 2008, 47: 47-54.
149. Rudd RM. Malignant mesothelioma. Br Med Bull 2010, 93: 105-23.
150. Shukla A, Bosenberg MW, MacPherson MB, et al. Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol 2009, 175: 2197-206.
151. Canettieri G, Celi FS, Baccheschi G, Salvatori L, Andreoli M, Centanni M. Isolation of human type 2 deiodinase gene promoter and characterization of a functional cyclic adenosine monophosphate response element. Endocrinology 2000, 141: 1804-13. (Pubitemid 32274411)
152. Meyers RL. Tumors of the liver in children. Surg Oncol 2007, 16: 195-203. (Pubitemid 350086944)
153. Kornasiewicz O, Debski M, Stepnowska M, Szałas A, Bar-Andziak E, Krawczyk M. The enzymatic activity of type 1 iodothyronine deiodinase (D1) is
154. Huang SA, Mulcahey MA, Crescenzi A, et al. Transforming growth factor-beta promotes inactivation of extracellular thyroid hormones via transcriptional stimulation of type 3 iodothyronine deiodinase. MoI Endocrinol 2005, 19: 3126-36. (Pubitemid 41697726)
155. Ito N, Kawata S, Tsushima H, et al. Increased circulating transforming growth factor beta1 in a patient with giant hepatic hemangioma: possible contribution to an impaired immune function. Hepatology 1997, 25: 93-6. (Pubitemid 27014991)
156. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003, 88: 3202-11. (Pubitemid 36877495)
157. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. Serum 3,3′,5′- triiodothyronine (rT3) and 3,5,3′- triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab 2005, 90: 4559-65. (Pubitemid 41159343)
158. Simonides WS, Mulcahey MA, Redout EM, et al. Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest 2008, 118: 975-83. (Pubitemid 351364605)
159. Kester MH, Toussaint MJ, Punt CA, et al. Large induction of type III deiodinase expression after partial hepatectomy in the regenerating mouse and rat liver. Endocrinology 2009, 150: 540-5.
160. Puzianowska-Kuznicka M, Nauman A, Madej A, Tanski Z, Cheng S, Nauman J. Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Lett 2000, 155: 145-52. (Pubitemid 30259128)
161. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A. Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 2002, 23: 25-33. (Pubitemid 34213548)
162. Rosen MD, Privalsky ML. Thyroid hormone receptor mutations found in renal clear cell carcinomas alter corepressor release and reveal helix 12 as key determinant of corepressor specificity. Mol Endocrinol 2009, 23: 1183-92.
163. Piekielko-Witkowska A, Wiszomirska H, Wojcicka A, et al. Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors. PLoS One 2010, 5: e13690.
164. Wu JX, Carpenter PM, Gresens C, et al. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 1990, 5: 989-1000.
165. Franchi A, Calzolari A, Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch 1998, 432: 515-9. (Pubitemid 28297558)
166. Gamberi G, Benassi MS, Bohling T, et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 1998, 55: 556-63. (Pubitemid 28479115)
167. Perez P, Schönthal A, Aranda A. Repression of c-fos gene expression by thyroid hormone and retinoic acid receptors. J Biol Chem 1993, 268: 23538-43. (Pubitemid 23328083)
168. Pérez-Juste G, García-Silva S, Aranda A. An element in the region responsible for premature termination of transcription mediates repression of c-myc gene expression by thyroid hormone in neuroblastoma cells. J Biol Chem 2000, 275: 1307-14. (Pubitemid 30051186)
169. Bellinger FP, Raman AV, Reeves MA, Berry MJ. Regulation and function of selenoproteins in human disease. Biochem J 2009, 422: 11-22.
170. Guigon CJ, Kim DW, Willingham MC, Cheng SY. Mutation of thyroid hormone receptor-β in mice predisposes to the development of mammary tumors. Oncogene 2011, 30: 3381-90.